Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating restated by stock analysts at Guggenheim in a research note issued on Tuesday,Benzinga reports.

Other equities research analysts have also issued reports about the company. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday. Finally, Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $13.38.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $2.07 on Tuesday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The business’s 50-day moving average is $2.28 and its 200-day moving average is $2.09. The company has a market capitalization of $286.25 million, a price-to-earnings ratio of -5.59 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Transactions at Compass Therapeutics

In other news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Anderman acquired 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares of the company’s stock, valued at $32,340. The trade was a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 28.50% of the company’s stock.

Institutional Trading of Compass Therapeutics

Several institutional investors have recently added to or reduced their stakes in CMPX. Tower Research Capital LLC TRC boosted its holdings in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance bought a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics in the fourth quarter worth $27,000. Mariner LLC bought a new stake in Compass Therapeutics during the 4th quarter valued at $30,000. Finally, Squarepoint Ops LLC purchased a new stake in Compass Therapeutics during the 4th quarter valued at $35,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.